Novo Nordisk, the Denmark-based pharmaceutical company that makes Ozempic and Wegovy, looks like it's being toppled off its GLP-1 throne. In a statement to Reuters, the Danish conglomerate admitted that it "currently [has] a hiring freeze in non-business critical areas. Though Novo offered no additional explanation, the writing has very much been on the wall for some months that the once-dominant drug manufacturer is in big financial trouble. Despite ushering in the weight-loss injectable craze and reaching a whopping $604 billion market cap in March 2024, Novo has for the past 18 months suffered hit after financial hit as compounding […]